Combining Nivolumab, Tacrolimus, and Prednisone for Post-Transplant Skin Cancer Treatment

A groundbreaking study published in the ASCO Journals has shed light on a potential treatment for advanced cutaneous squamous cell carcinoma (CSCC) in kidney transplant recipients. The study, led by Dr. JCO, examined the use of a combination therapy using nivolumab, tacrolimus, prednisone, and ipilimumab.

The research involved 26 patients who received a kidney transplant and later developed advanced CSCC. The combination therapy showed promising results, with an overall response rate of 60% and a complete response rate of 35%. This suggests that the treatment could be effective in shrinking or eliminating tumors in these patients.

The study findings have significant implications for the treatment of advanced CSCC in kidney transplant recipients, as it offers a potential alternative to traditional therapies. The combination of nivolumab, tacrolimus, prednisone, and ipilimumab could potentially provide a more effective and targeted approach to treating this specific patient population. These findings open up new avenues for research and the development of personalized treatments for cancer patients with a history of organ transplantation.

Help improve our content system

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

Share this story:

Transplant News
Transplant News

Transplant News brings you the news and content that matters to the transplant community. From patient stories, to the latest in transplant innovation, Transplant News is your window into the world of transplantation.